Does holding at 1 mg for two weeks before escalating reduce hair thinning?

Stated plainly: 1 mg · two weeks · hair thinning.

I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.

My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.

What is the causal chain, and where does it stop being established?

The honest answer is that going slower costs time and nothing else, since the exposure ceiling is unchanged.

Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.

Stated carefully, the published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.

The caveat is that titration decisions belong with a clinician who knows what else is on board.

Stepping back is a normal adjustment, not a failure.

edited 2 Sept 2025 by cal_hennessy — added the method parameters

Start with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.

The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.

Put another way, for an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.

Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.

Slower costs time and nothing else. The ceiling is the same.

Answer first: the titration schedule exists to let tolerance to the gastrointestinal effects develop between steps, and every step in it is a tolerability decision rather than an efficacy one.

Titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.

Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.

Four half-lives between steps, minimum. Work it out for your agent.

This is the single most consequential controllable variable in the whole experience, and people routinely rush it.

The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.

Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.

The top of the schedule is not the target. The working dose is.